Drug monitoring and individual dose optimization of antimicrobial drugs: Oxazolidinones

Expert Opinion on Drug Metabolism and Toxicology

Volumn 12, Issue 5, 2016, Pages 533-544

  Cattaneo, Dario ^a   Alffenaar, Jan Willem ^b   Neely, Michael ^c,d  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c CHILDREN S HOSPITAL LOS ANGELES   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Dose optimization; linezolid; oxazolidinones; pharmacokinetics; tedizolid; therapeutic drug monitoring

Indexed keywords

LINEZOLID; TEDIZOLID; ANTIINFECTIVE AGENT; OXAZOLIDINONE DERIVATIVE; TETRAZOLE DERIVATIVE;

BODY WEIGHT; CHILDHOOD DISEASE; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; HUMAN; KIDNEY FUNCTION; META ANALYSIS; RENAL CLEARANCE; REVIEW; SYSTEMATIC REVIEW; TUBERCULOSIS; ANIMAL; BACTERIAL INFECTION; DOSE RESPONSE; MICROBIOLOGY; PERSONALIZED MEDICINE; PROCEDURES;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; HUMANS; LINEZOLID; OXAZOLIDINONES; PRECISION MEDICINE; TETRAZOLES;

EID: 84961661943     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2016.1166204     Document Type: Review

References (91)

1. Shaw KJ, Barbachyn MR. The oxazolidinones: past, present, and future. Ann N Y Acad Sci. 2011; 1241:48-70.
2. Spangler SK, Jacobs MR, Appelbaum PC. Activities of RPR 106972 (a new oral streptogramin), cefditoren (a new oral cephalosporin), two new oxazolidinones (U-100592 and U-100766), and other oral and parenteral agents against 203 penicillin-susceptible and -resistant pneumococci. Antimicrob Agents Chemother. 1996; 40:481-484.
3. Gordeev MF, Yuan ZY. New potent antibacterial oxazolidinone (MRX-I) with an improved class safety profile. J Med Chem. 2014; 57:4487-4497.
4. Diekema DJ, Jones RN. Oxazolidinone antibiotics. Lancet. 2001; 358:1975-1982.
5. Vardakas KZ, Ntziora F, Falagas ME. Linezolid: effectiveness and safety for approved and off-label indications. Expert Opin Pharmacother. 2007; 8:2381-2400.
6. O'Riordan W, Green S, Mehra P, et al. Tedizolid phosphate for the management of acute bacterial skin and skin structure infections: efficacy summary. Clin Infect Dis. 2014; 58 (Suppl 1): S43-S50.
7. Metaxas EI, Falagas ME. Update on the safety of linezolid. Expert Opin Drug Saf. 2009; 8:485-491.
8. Mendes RE, Deshpande LM, Jones RN. Linezolid update: stable in vitro activity following more than a decade of clinical use and summary of associated resistance mechanisms. Drug Resist Updat. 2014; 17:1-12.
9. Villar M, Sotgiu G, D'Ambrosio L, et al. Linezolid safety, tolerability and efficacy to treat multidrug- and extensively drug-resistant tuberculosis. Eur Respir J. 2011; 38:730-733.
10. Lee M, Lee J, Carroll MW, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med. 2012; 367:1508-1518.
11. Zhang X, Falagas ME, Vardakas KZ, et al. Systematic review and meta-analysis of the efficacy and safety of therapy with linezolid containing regimens in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis. J Thorac Dis. 2015; 7:603-615.
12. Douros A, Grabowski K, Stahlmann R. Drug-drug interactions and safety of linezolid, tedizolid, and other oxazolidinones. Expert Opin Drug Metab Toxicol. 2015; 11:1849-1859.
13. Di Paolo A, Malacarne P, Guidotti E, et al. Pharmacological issues of linezolid: an updated critical review. Clin Pharmacokinet. 2010; 49:439-447.
14. Dryden MS. Linezolid pharmacokinetics and pharmacodynamics in clinical treatment. J Antimicrob Chemother. 2011; 66 (Suppl 4): iv7-iv15.
15. Cattaneo D, Orlando G, Cozzi V, et al. Linezolid plasma concentrations and occurrence of drug-related haematological toxicity in patients with gram-positive infections. Int J Antimicrob Agents. 2013; 41:586-589.
16. Gervasoni C, Cozzi V, Charbe N, et al. Risk factors for linezolidassociated thrombocytopenia in adult patients. XIV National SIMIT Congress; 2015 November 9-11; Catania. Abstract n.155.
17. Cossu AP, Musu M, Mura P, et al. Linezolid-induced thrombocytopenia in impaired renal function: is it time for a dose adjustment? A case report and review of literature. Eur J Clin Pharmacol. 2014; 70:23-28.
18. Brier ME, Stalker DJ, Aronoff GR, et al. Pharmacokinetics of linezolid in subjects with renal dysfunction. Antimicrob Agents Chemother. 2003; 47:2775-2780.
19. Matsumoto K, Takeshita A, Ikawa K, et al. Higher linezolid exposure and higher frequency of thrombocytopenia in patients with renal dysfunction. Int J Antimicrob Agents. 2010; 36:179-181.
20. Tsuji Y, Hiraki Y, Matsumoto K, et al. Thrombocytopenia and anemia caused by a persistent high linezolid concentration in patients with renal dysfunction. J Infect Chemother. 2011; 17:70-75.
21. Tsuji Y, Yukawa E, Hiraki Y, et al. Population pharmacokinetic analysis of linezolid in low body weight patients with renal dysfunction. J Clin Pharmacol. 2013; 53:967-973.
22. Nukui Y, Hatakeyama S, Okamoto K, et al. High plasma linezolid concentration and impaired renal function affect development of linezolid-induced thrombocytopenia. J Antimicrob Chemother. 2013; 68:2128-2133.
23. Matsumoto K, Shigemi A, Takeshita A, et al. Analysis of thrombocytopenic effects and population pharmacokinetics of linezolid: a dosage strategy according to the trough concentration target and renal function in adult patients. Int J Antimicrob Agents. 2014; 44:242-247.
24. Fiaccadori E, Maggiore U, Rotelli C, et al. Does haemodialysis significantly affect serum linezolid concentrations in critically ill patients with renal failure? A pilot investigation. Nephrol Dial Transplant. 2006; 21:1402-1406.
25. El-Assal MI, Helmy SA. Single-dose linezolid pharmacokinetics in critically ill patients with impaired renal function especially chronic hemodialysis patients. Biopharm Drug Dispos. 2014; 35:405-416.
26. Villa G, Cassetta MI, Tofani L, et al. Linezolid extracorporeal removal during haemodialysis with high cut-off membrane in critically ill patients. Int J Antimicrob Agents. 2015; 46:465-468.
27. Roger C, Muller L, Wallis SC, et al. Population pharmacokinetics of linezolid in critically ill patients on renal replacement therapy: comparison of equal doses in continuous venovenous haemofiltration and continuous venovenous haemodiafiltration. J Antimicrob Chemother. 2016; 71:464-470.
28. Carcelero E, Soy D, Guerrero L, et al. Linezolid pharmacokinetics in patients with acute renal failure undergoing continuous venovenous hemodiafiltration. J Clin Pharmacol. 2012; 52:1430-1435.
29. Hiraki Y, Tsuji Y, Misumi N, et al. Pharmacokinetics and elimination efficiency of linezolid during dialysis. Ren Fail. 2013; 35:418-420.
30. Gervasoni C, Bergia R, Cozzi V, et al. Is it time to revise linezolid doses in peritoneal dialysis patients? A case series. J Antimicrob Chemother. 2015; 70:2918-2920.
31. Abe S, Chiba K, Cirincione B, et al. Population pharmacokinetic analysis of linezolid in patients with infectious disease: application to lower body weight and elderly patients. J Clin Pharmacol. 2009; 49:1071-1078.
32. Stein GE, Schooley SL, Peloquin CA, et al. Pharmacokinetics and pharmacodynamics of linezolid in obese patients with cellulitis. Ann Pharmacother. 2005; 39:427-432.
33. Tsuji Y, Hiraki Y, Matsumoto K, et al. Evaluation of the pharmacokinetics of linezolid in an obese Japanese patient. Scand J Infect Dis. 2012; 44:626-629.
34. Hamilton R, Thai XC, Ameri D, et al. Oral bioavailability of linezolid before and after Roux-en-Y gastric bypass surgery: is dose modification necessary in obese subjects? J Antimicrob Chemother. 2013; 68:666-673.
35. Bhalodi AA, Papasavas PK, Tishler DS, et al. Pharmacokinetics of intravenous linezolid in moderately to morbidly obese adults. Antimicrob Agents Chemother. 2013; 57:1144-1149.
36. Corcione S, Pagani N, Baietto L, et al. Pharmacokinetics of high dosage of linezolid in two morbidly obese patients. J Antimicrob Chemother. 2015; 70:2417-2418.
37. Lovering AM, Zhang J, Bannister GC, et al. Penetration of linezolid into bone, fat, muscle and haematoma of patients undergoing routine hip replacement. J Antimicrob Chemother. 2002; 50:73-77.
38. Sisson TL, Jungbluth GL, Hopkins NK. Age and sex effects on the pharmacokinetics of linezolid. Eur J Clin Pharmacol. 2002; 57:793-797.
39. Wynalda MA, Hauer MJ, Wienkers LC. Oxidation of the novel oxazolidinone antibiotic linezolid in human liver microsomes. Drug Metab Dispos. 2000; 28:1014-1017.
40. Gervasoni C, Simonetti FR, Resnati C, et al. Prolonged inductive effect of rifampicin on linezolid exposure. Eur J Clin Pharmacol. 2015; 71:643-644.
41. Pea F, Viale P, Cojutti P, et al. Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients. J Antimicrob Chemother. 2012; 67:2034-2042.
42. Bolhuis MS, Van Altena R, Van Soolingen D, et al. Clarithromycin increases linezolid exposure in multidrug-resistant tuberculosis patients. Eur Respir J. 2013; 42:1614-1621.
43. Sakai Y, Naito T, Arima C, et al. Potential drug interaction between warfarin and linezolid. Intern Med. 2015; 54:459-464.
44. Wu VC, Wang YT, Wang CY, et al. High frequency of linezolidassociated thrombocytopenia and anemia among patients with end-stage renal disease. Clin Infect Dis. 2006; 42:66-72.
45. Tsuji Y, Hiraki Y, Mizoguchi A, et al. Pharmacokinetics of repeated dosing of linezolid in a hemodialysis patient with chronic renal failure. J Infect Chemother. 2008; 14:156-160.
46. Niwa T, Watanabe T, Suzuki A, et al. Reduction of linezolid-associated thrombocytopenia by the dose adjustment based on the risk factors such as basal platelet count and body weight. Diagn Microbiol Infect Dis. 2014; 79:93-97.
47. Ichie T, Suzuki D, Yasui K, et al. The association between risk factors and time of onset for thrombocytopenia in Japanese patients receiving linezolid therapy: a retrospective analysis. J Clin Pharm Ther. 2015; 40:279-284.
48. Hiraki Y, Tsuji Y, Hiraike M, et al. Correlation between serum linezolid concentration and the development of thrombocytopenia. Scand J Infect Dis. 2012; 44:60-64.
49. Boak LM, Rayner CR, Grayson ML, et al. Clinical population pharmacokinetics and toxicodynamics of linezolid. Antimicrob Agents Chemother. 2014; 58:2334-2343.
50. Alffenaar JW, Kosterink JG, Van Altena R, et al. Limited sampling strategies for therapeutic drug monitoring of linezolid in patients with multidrug-resistant tuberculosis. Ther Drug Monit. 2010; 32:97-101.
51. Alffenaar JW, Van Altena R, Harmelink IM, et al. Comparison of the pharmacokinetics of two dosage regimens of linezolid in multidrug- resistant and extensively drug-resistant tuberculosis patients. Clin Pharmacokinet. 2010; 49:559-565.
52. Dong H, Xie J, Chen L, et al. Developments in the pharmacokinetic/pharmacodynamic index of linezolid: a step toward dose optimization using Monte Carlo simulation in critically ill patients. Int J Infect Dis. 2014; 22:35-40.
53. Jacqueline C, Batard E, Perez L, et al. In vivo efficacy of continuous infusion versus intermittent dosing of linezolid compared to vancomycin in a methicillin-resistant Staphylococcus aureus rabbit endocarditis model. Antimicrob Agents Chemother. 2002; 46:3706-3711.
54. Linezolid - EUCAST Rationale document [cited 2015 Feb 1] Available from: www.eucast.org/fileadmin/src/media/PDFs/EUCAST-files/Rationale-documents/Linezolidrationale1.0.pdf.
55. Ashizawa N, Tsuji Y, Kawago K, et al. Successful treatment of methicillin-resistant Staphylococcus aureus osteomyelitis with combination therapy using linezolid and rifampicin under therapeutic drug monitoring. J Infect Chemother. 2015; pii: S1341- 321X (15)00284-6. doi:10.1016/j.jiac.2015.11.012. Epub ahead of print
56. Roberts JA, Abdul-Aziz MH, Lipman J, et al. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis. 2014; 14:498-509.
57. Lopez-Garcia B, Luque S, Roberts JA, et al. Pharmacokinetics and preliminary safety of high dose linezolid for the treatment of Grampositive bacterial infections. J Infect. 2015; 71:604-607.
58. Weiss T, Schönfeld N, Otto-Knapp R, et al. Low minimal inhibitory concentrations of linezolid against multidrug-resistant tuberculosis strains. Eur Respir J. 2015; 45:285-287.
59. Migliori GB, Eker B, Richardson MD, et al. A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug- resistant tuberculosis. Eur Respir J. 2009; 34:387-393.
60. Yew WW, Chang KC, Chau CH. What is the optimal dosage of linezolid in treatment of complicated multidrug-resistant tuberculosis? Eur Respir J. 2009; 34:1492-1494.
61. Koh WJ, Kang YR, Jeon K, et al. Daily 300 mg dose of linezolid for multidrug-resistant and extensively drug-resistant tuberculosis: updated analysis of 51 patients. J Antimicrob Chemother. 2012; 67:1503-1507.
62. De Lorenzo S, Alffenaar JW, Sotgiu G, et al. Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB. Eur Respir J. 2013; 41:1386-1392.
63. Yew WW, Chang KC, Chau CH. Comment on: Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis. J Antimicrob Chemother. 2009; 64:1119.
64. Bolhuis MS, Van Altena R, Van Hateren K, et al. Clinical validation of the analysis of linezolid and clarithromycin in oral fluid of patients with multidrug-resistant tuberculosis. Antimicrob Agents Chemother. 2013; 57:3676-3680.
65. Heysell SK, Moore JL, Peloquin CA, et al. Outcomes and use of therapeutic drug monitoring in multidrug-resistant tuberculosis patients treated in virginia, 2009-2014. Tuberc Respir Dis (Seoul). 2015; 78:78-84.
66. Bolhuis MS, Tiberi S, Sotgiu G, et al. Linezolid tolerability in multidrug- resistant tuberculosis: a retrospective study. Eur Respir J. 2015; 46:1205-1207.
67. Chiappini E, Conti C, Galli L, et al. Clinical efficacy and tolerability of linezolid in pediatric patients: a systematic review. Clin Ther. 2010; 32:66-88.
68. Kocher S, Müller W, Resch B. Linezolid treatment of nosocomial bacterial infection with multiresistant gram-positive pathogens in preterm infants: a systematic review. Int J Antimicrob Agents. 2010; 36:106-110.
69. Cojutti P, Maximova N, Crichiutti G, et al. Pharmacokinetic/pharmacodynamic evaluation of linezolid in hospitalized paediatric patients: a step toward dose optimization by means of therapeutic drug monitoring and Monte Carlo simulation. J Antimicrob Chemother. 2015; 70:198-206.
70. Kosaka T, Kokufu T, Shime N, et al. Pharmacokinetics and tolerance of linezolid for meticillin-resistant Staphylococcus aureus mediastinitis in paediatric patients. Int J Antimicrob Agents. 2009; 33:368-370.
71. Matsumoto K, Shigemi A, Takeshita A, et al. Linezolid dosage in pediatric patients based on pharmacokinetics and pharmacodynamics. J Infect Chemother. 2015; 21:70-73.
72. Simon A, Müllenborn E, Prelog M, et al. Use of linezolid in neonatal and pediatric inpatient facilities-results of a retrospective multicenter survey. Eur J Clin Microbiol Infect Dis. 2012; 31:1435-1442.
73. Sicard M, Launay E, Caillon J, et al. Pharmacokinetics of linezolid treatment using intravenous and oral administrations in extremely premature infants. Eur J Clin Pharmacol. 2015; 71:611-615.
74. Garcia-Prats AJ, Rose PC, Hesseling AC, et al. Linezolid for the treatment of drug-resistant tuberculosis in children: a review and recommendations. Tuberculosis (Edinb). 2014; 94:93-104.
75. Zhanel GG, Love R, Adam H, et al. Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens. Drugs. 2015; 75:253-270.
76. Hall RG 2nd, Michaels HN. Profile of tedizolid phosphate and its potential in the treatment of acute bacterial skin and skin structure infections. Infect Drug Resist. 2015; 8:75-82.
77. Lodise TP, Drusano GL. Use of pharmacokinetic/pharmacodynamic systems analyses to inform dose selection of tedizolid phosphate. Clin Infect Dis. 2014; 58 (Suppl 1): S28-34.
78. Ong V, Flanagan S, Fang E, et al. Absorption, distribution, metabolism, and excretion of the novel antibacterial prodrug tedizolid phosphate. Drug Metab Dispos. 2014; 42:1275-1284.
79. Flanagan S, Passarell J, Lu Q, et al. Tedizolid population pharmacokinetics, exposure response, and target attainment. Antimicrob Agents Chemother. 2014; 58:6462-6470.
80. Flanagan S, Fang E, Muñoz KA, et al. Single- and multiple-dose pharmacokinetics and absolute bioavailability of tedizolid. Pharmacotherapy. 2014; 34:891-900.
81. Flanagan S, Minassian SL, Morris D, et al. Pharmacokinetics of tedizolid in subjects with renal or hepatic impairment. Antimicrob Agents Chemother. 2014; 58:6471-6476.
82. Sahre M, Sabarinath S, Grant M, et al. Skin and soft tissue concentrations of tedizolid (formerly torezolid), a novel oxazolidinone, following a single oral dose in healthy volunteers. Int J Antimicrob Agents. 2012; 40:51-54.
83. Roberts JA, Pea F, Lipman J. The clinical relevance of plasma protein binding changes. Clin Pharmacokinet. 2013; 52:1-8.
84. Molina-Torres CA, Barba-Marines A, Valles-Guerra O, et al. Intracellular activity of tedizolid phosphate and ACH-702 versus Mycobacterium tuberculosis infected macrophages. Ann Clin Microbiol Antimicrob. 2014; 13:13.
85. Drusano GL, Liu W, Kulawy R, et al. Impact of granulocytes on the antimicrobial effect of tedizolid in a mouse thigh infection model. Antimicrob Agents Chemother. 2011; 55:5300-5305.
86. Shorr AF, Lodise TP, Corey GR, et al. Analysis of the phase 3 ESTABLISH trials of tedizolid versus linezolid in acute bacterial skin and skin structure infections. Antimicrob Agents Chemother. 2015; 59:864-871.
87. Neely M, Jelliffe R. Practical therapeutic drug management in HIVinfected patients: use of population pharmacokinetic models supplemented by individualized Bayesian dose optimization. J Clin Pharmacol. 2008; 48:1081-1091.
88. Tørset E, ?sberg A, Skauby M, et al. Improved tacrolimus target concentration achievement using computerized dosing in renal transplant recipients-a prospective, randomized study. Transplantation. 2015; 99:2158-2166.
89. Neely M, Margol A, Fu X, et al. Achieving target voriconazole concentrations more accurately in children and adolescents. Antimicrob Agents Chemother. 2015; 59:3090-3097.
90. Hofman S, Bolhuis MS, Koster RA, et al. Role of therapeutic drug monitoring in pulmonary infections: use and potential for expanded use of dried blood spot samples. Bioanalysis. 2015; 7:481-495.
91. Housman ST, Pope JS, Russomanno J, et al. Pulmonary disposition of tedizolid following administration of once-daily oral 200-milligram tedizolid phosphate in healthy adult volunteers. Antimicrob Agents Chemother. 2012; 56:2627-2634.